A recent study reported that RORA agonists attenuated fatty liver progression in NAFLD mice and regulate hepatic lipid homeostasis by modulating PPARγ [32, 33]. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.